» Articles » PMID: 30398435

Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study

Overview
Journal Radiology
Specialty Radiology
Date 2018 Nov 7
PMID 30398435
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose To investigate ferumoxytol-enhanced MRI as a noninvasive imaging biomarker of macrophages in adults with high-grade gliomas. Materials and Methods In this prospective study, adults with high-grade gliomas were enrolled between July 2015 and July 2017. Each participant was administered intravenous ferumoxytol (5 mg/kg) and underwent 3.0-T MRI 24 hours later. Two sites in each tumor were selected for intraoperative sampling on the basis of the degree of ferumoxytol-induced signal change. Susceptibility and the relaxation rates R2* (1/T2*) and R2 (1/T2) were obtained by region-of-interest analysis by using the respective postprocessed maps. Each sample was stained with Prussian blue, CD68, CD163, and glial fibrillary acidic protein. Pearson correlation and linear mixed models were performed to assess the relationship between imaging measurements and number of 400× magnification high-power fields with iron-containing macrophages. Results Ten adults (four male participants [mean age, 65 years ± 9 {standard deviation}; age range, 57-74 years] and six female participants [mean age, 53 years ± 12 years; age range, 32-65 years]; mean age of all participants, 58 years ± 12 [age range, 32-74 years]) with high-grade gliomas were included. Significant positive correlations were found between susceptibility, R2*, and R2' and the number of high-power fields with CD163-positive (r range, 0.64-0.71; P < .01) and CD68-positive (r range, 0.55-0.57; P value range, .01-.02) iron-containing macrophages. No significant correlation was found between R2 and CD163-positive (r = 0.33; P = .16) and CD68-positive (r = 0.24; P = .32) iron-containing macrophages. Similar significance results were obtained with linear mixed models. At histopathologic analysis, iron particles were found only in macrophages; none was found in glial fibrillary acidic protein-positive tumor cells. Conclusion MRI measurements of susceptibility, R2*, and R2' (R2* - R2) obtained after ferumoxytol administration correlate with iron-containing macrophage concentration, and this shows their potential as quantitative imaging markers of macrophages in malignant gliomas. © RSNA, 2018 Online supplemental material is available for this article.

Citing Articles

Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification.

Sehl O, Yang Y, Anjier A, Nevozhay D, Cheng D, Guo K Mol Imaging Biol. 2024; 27(1):78-88.

PMID: 39653984 DOI: 10.1007/s11307-024-01969-z.


Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery.

Xie M, Meng F, Wang P, Diaz-Garcia A, Parkhats M, Santos-Oliveira R Int J Nanomedicine. 2024; 19:8437-8461.

PMID: 39170101 PMC: 11338174. DOI: 10.2147/IJN.S477652.


Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials.

Lapusan R, Borlan R, Focsan M Nanoscale Adv. 2024; 6(9):2234-2259.

PMID: 38694462 PMC: 11059564. DOI: 10.1039/d3na01064c.


Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.

Si G, Du Y, Tang P, Ma G, Jia Z, Zhou X Natl Sci Rev. 2024; 11(5):nwae057.

PMID: 38577664 PMC: 10989670. DOI: 10.1093/nsr/nwae057.


Glioblastoma stem cell-derived exosomal miR-374b-3p promotes tumor angiogenesis and progression through inducing M2 macrophages polarization.

Huang S, Zhang P, Yin N, Xu Z, Liu X, Wu A iScience. 2024; 27(3):109270.

PMID: 38487014 PMC: 10937837. DOI: 10.1016/j.isci.2024.109270.


References
1.
Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K . Quantitative MR imaging of brain iron: a postmortem validation study. Radiology. 2010; 257(2):455-62. DOI: 10.1148/radiol.10100495. View

2.
Daldrup-Link H, Golovko D, Ruffell B, DeNardo D, Castaneda R, Ansari C . MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res. 2011; 17(17):5695-704. PMC: 3166957. DOI: 10.1158/1078-0432.CCR-10-3420. View

3.
Langkammer C, Liu T, Khalil M, Enzinger C, Jehna M, Fuchs S . Quantitative susceptibility mapping in multiple sclerosis. Radiology. 2013; 267(2):551-9. PMC: 3632806. DOI: 10.1148/radiol.12120707. View

4.
Liu T, Khalidov I, de Rochefort L, Spincemaille P, Liu J, Tsiouris A . A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed. 2011; 24(9):1129-36. PMC: 3628923. DOI: 10.1002/nbm.1670. View

5.
Engler J, Robinson A, Smirnov I, Hodgson J, Berger M, Gupta N . Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One. 2012; 7(8):e43339. PMC: 3425586. DOI: 10.1371/journal.pone.0043339. View